Clinical trial · Observational
SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
NCT03604211CI-TRIAL-00034426completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Metastases | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyberknife Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- time to biochemical recurrence
- timeFrame
- 18 months
- description
- time interval from SBRT until second PSA rise
Secondary outcomes (2)
- measure
- biochemical response rate
- timeFrame
- 18 months
- description
- reduction by at least 10% of the initial PSA value
- measure
- time interval between SBRT and ADT start
- timeFrame
- 18 months
- description
- time interval between SBRT and ADT start
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * histologically proven diagnosis of prostate cancer * Radical prostatectomy (± salvage radiotherapy) * PSA relapse (defined by two consecutive rising PSA values \>0.2 ug/l) * one to three lymphnodes positive on Choline-PET * no recurrence in prostatic bed on Choline-PET * WHO performance status of 0-1 * no previous chemotherapy or ADT for prostate cancer. Exclusion Criteria: * primary treatment for prostate cancer by RT or brachytherapy * bone (M1b) metastases * visceral (M1c) metastases * any symptomatic nodal lesion
References
Publications (0)
Data not yet available
No reference posted for this study.